Beghetti, Maurice <br/><br/>
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.  [electronic resource] 

 -  European journal of heart failure  03 2019 
 - 352-359 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0844 
<br/><br/><label>Standard No.: </label>10.1002/ejhf.1375  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetamides--administration & dosage<br/>Adult<br/>Antihypertensive Agents--administration & dosage<br/>Cardiac Surgical Procedures--adverse effects<br/>Disease Progression<br/>Double-Blind Method<br/>Drug Monitoring--methods<br/>Early Medical Intervention--methods<br/>Female<br/>Heart Defects, Congenital--complications<br/>Humans<br/>Hypertension, Pulmonary--diagnosis<br/>Male<br/>Middle Aged<br/>Proportional Hazards Models<br/>Pyrazines--administration & dosage<br/>Treatment Outcome